TD Asset Management Inc Grows Position in Bristol Myers Squibb Company $BMY

TD Asset Management Inc increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 51.4% in the second quarter, Holdings Channel reports. The firm owned 2,007,448 shares of the biopharmaceutical company’s stock after buying an additional 681,472 shares during the period. TD Asset Management Inc’s holdings in Bristol Myers Squibb were worth $115,669,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. waypoint wealth counsel acquired a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $1,194,000. Life Cycle Investment Partners Ltd acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at approximately $34,406,000. Lazard Asset Management LLC lifted its stake in Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after purchasing an additional 368,193 shares in the last quarter. Axxcess Wealth Management LLC lifted its stake in Bristol Myers Squibb by 27.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after purchasing an additional 21,196 shares in the last quarter. Finally, Asset One Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter worth $4,075,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on BMY shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. TD Cowen began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating for the company. Royal Bank Of Canada lifted their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, July 30th. Finally, Raymond James Financial assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $63.86 on Friday. The business has a 50-day simple moving average of $59.56 and a 200-day simple moving average of $58.97. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.10. The company has a market cap of $130.45 billion, a PE ratio of 14.07, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter last year, the company earned $1.46 earnings per share. The firm’s revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.